242 related articles for article (PubMed ID: 24443367)
1. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
3. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
4. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.
Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD
Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269
[TBL] [Abstract][Full Text] [Related]
7. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men.
Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L
Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
[TBL] [Abstract][Full Text] [Related]
12. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of prostate cancer screening test as a national cancer screening program in South Korea.
Shin S; Kim YH; Hwang JS; Lee YJ; Lee SM; Ahn J
Asian Pac J Cancer Prev; 2014; 15(8):3383-9. PubMed ID: 24870726
[TBL] [Abstract][Full Text] [Related]
14. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.
Carlsson SV; de Carvalho TM; Roobol MJ; Hugosson J; Auvinen A; Kwiatkowski M; Villers A; Zappa M; Nelen V; Páez A; Eastham JA; Lilja H; de Koning HJ; Vickers AJ; Heijnsdijk EA
Cancer; 2016 Nov; 122(21):3386-3393. PubMed ID: 27459245
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
Keeney E; Sanghera S; Martin RM; Gulati R; Wiklund F; Walsh EI; Donovan JL; Hamdy F; Neal DE; Lane JA; Turner EL; Thom H; Clements MS
Pharmacoeconomics; 2022 Dec; 40(12):1207-1220. PubMed ID: 36201131
[TBL] [Abstract][Full Text] [Related]
16. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
[TBL] [Abstract][Full Text] [Related]
18. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
19. Quality-of-life effects of prostate-specific antigen screening.
Heijnsdijk EA; Wever EM; Auvinen A; Hugosson J; Ciatto S; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Zappa M; Tammela TL; Mäkinen T; Carlsson S; Korfage IJ; Essink-Bot ML; Otto SJ; Draisma G; Bangma CH; Roobol MJ; Schröder FH; de Koning HJ
N Engl J Med; 2012 Aug; 367(7):595-605. PubMed ID: 22894572
[TBL] [Abstract][Full Text] [Related]
20. Optimization of PSA screening policies: a comparison of the patient and societal perspectives.
Zhang J; Denton BT; Balasubramanian H; Shah ND; Inman BA
Med Decis Making; 2012; 32(2):337-49. PubMed ID: 21933990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]